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Introduction
Muscular dystrophies (MDs) 1 are genetically inherited myogenic disorders characterized by progressive muscle wasting and weakness of variable distribution and severity [1] . These symptoms are caused by cycles of myofiber degeneration-regeneration, myofiber necrosis, and the initiation of the dystrophy [2] , resulting in the general pathologies of MDs, such as increased fibrosis, appearance of smaller and split myofibers, and reduced muscle mass [3] [4] [5] . The dysferlinopathies are a group of non-lethal MDs with late phenotype onset, occurring in the second or third decades of life, as opposed to other MDs such as Duchenne MD (DMD) and congenital MD (CMD) [6] [7] [8] . Although considered milder than DMD and CMD, the dysferlinopathy pathologies can severely compromise patients' quality of life [9] .
Dysferlinopathies are caused by mutations in the dysferlin gene (DYSF) located on chromosome 2p13. This gene encodes the ubiquitous 230-kD transmembranal dysferlin protein, located in high abundance on the sarcolemma of heart and skeletal myofibers [8, 10, 11] .
Dysferlin has been reported to initiate the patch-repair protein complex activity that is involved in the repair of microscopic tears of the sarcolemma, and in the final stages of membrane fusion during myofiber regeneration [12, 13] . Therefore, absence of dysferlin leads to delays in myofiber fusion and deficiencies in membrane resealing [3, 14] . The earliest pathological signs of dysferlinopathies have been described in biopsies derived from 13-year-old patients, and current treatments focus mainly on post-disease onset [15] [16] [17] [18] [19] . The earliest pathological signs in mouse models for dysferlinopathies have been described in 8-week-old A/J-modified and 3-
Results

Primary myoblasts from 5-week-old dysf -/mice show delayed fusion in culture
The involvement of dysferlin in membrane resealing raised the possibility of its involvement in muscle cell differentiation and myotube fusion [3, 8, 10, 31] . Here, we addressed the differentiation and fusion abilities of dysf -/muscle cells derived from 5-week-old mice. Primary myoblasts of Wt and dysf -/mice were induced to differentiate, and their differentiation state was monitored by immunostaining for MyHC, a marker for muscle cell terminal differentiation. On days 2 and 5, thinner dysf -/myotubes were observed compared to the relatively thicker Wt myotubes ( Fig 1A) . In addition, on day 2, despite a comparable number of nuclei in Wt and dysf -/primary cell culture, the dysf -/myotubes showed delayed fusion activity; these myotubes were observed mainly in areas populated by less nuclei. On day 8, although many dysf -/myotubes were observed, they were still much thinner than those of Wt origin (Fig. 1A) . The fusion index was calculated as the percentage of myotubes in each group for 2-5, 6-15 ( Fig. 1B ) and >15 ( Fig. 1C ) nuclei per myotube out of the total number of myotubes on each day. In the groups representing the smaller myotubes, the fusion index was similar in the Wt and dystrophic myotubes on all days ( Fig. 1B) . In contrast, the percentage of myotubes containing over 15 nuclei per myotube was zero on day 2 and significantly lower on day 8 in the dysf -/derived cultures compared to their Wt-counterparts ( Fig. 1C ).
Halofuginone has a promotive effect on dysf -/myotube fusion in vitro
The above results suggested a delay in myoblast differentiation and myotube fusion in cultures derived from dysf -/mice at as early as 5 weeks of age. The delay in fusion might be due to impaired cell-cell connections by actin filaments-finger-like actin-based protrusions that have a role in cell movement and cell-cell fusion in many cell types, including satellite cells [42] [43] [44] [45] .
In this study, the previously reported promotive effect of halofuginone on the dysf -/fusion index [27] was evaluated with regard to alterations in actin filaments and myotube fusion. Primary myoblasts of dysf -/mice were induced to differentiate for 24 h as described in Fig. 1 , followed by incubation with or without 10 nM halofuginone for another 24 h. The myotubes were then fixed and visualized by SEM. Under low magnification, in the non-treated myotubes, a single thin elongated myotube (white arrow in Fig. 2A ) was viewed with no noticeable fusion connections to the adjacent muscle cells. However, in the halofuginone-treated myotubes, a myotube of similar size appeared to have many filaments, presumably actin filaments [44, [46] [47] [48] , connecting it to other myotubes ( Fig. 2B , yellow arrows). Under higher magnification, many filament connections were noticed in the halofuginone-treated myotubes ( Fig. 2D ) compared to the non-treated myotube, which barely presented any connecting filaments ( Fig. 2C ).
Treatment with halofuginone decreases the levels of fibrosis and P-Smad3 in young dysf -/-
mice In light of the results indicating impaired myotube fusion in cultures derived from young dysf -/mice, and the promotive effect of halofuginone on this process, we next tested halofuginone's effects on fibrosis in young dysf -/mice at early stages of disease progression. Mice were treated, or not, with halofuginone from 4 weeks of age to 5 months of age (i.p. injections of either 7.5 μg halofuginone or saline, respectively, three times per week [25, 26] ). Hindlimb muscle sections of 4-week-old and 5-month-old Wt and non-treated or halofuginonetreated dysf -/mice were stained with Sirius red to evaluate collagen (type I and III) content in the fibrotic tissue. Unlike in the Wt muscle sections ( Fig. 3Aa ), collagen staining was already notable in the myofiber fascicles of the dysf -/muscle sections at 4 weeks of age ( Fig. 3Ab ). Quantitative analysis revealed a collagen content of about 0.5% in 4-week-old Wt muscle sections, whereas in the dysf -/muscle sections, the percentage was approximately double that ( Fig. 3B ). At 5 months of age, in contrast to the Wt mice ( Fig. 3Ac ), the amount of collagen staining in the muscle sections was further increased in the non-treated dysf -/mice ( Fig. 3Ad ) and was over threefold higher in the latter compared to the Wt (Fig. 3B ). Treatment with halofuginone from the age of 4 weeks to 5 months reduced the collagen content in the muscle sections back to Wt levels ( Fig. 3Ae ). Collagen content was almost negligible in these mice and comparable to the levels in Wt mice (Fig. 3B ).
The reduction in fibrosis correlated with the reduction in P-Smad3 levels: western blot analysis of protein lysates derived from hindlimb muscles of 5-month-old dysf -/mice revealed fivefold lower P-Smad3 levels in the halofuginonetreated mice than in their non-treated counterparts (Fig.   3C ).
Halofuginone improves muscle histopathology and motor coordination of 5-month-old dysf -/-mice
Quadriceps muscle sections of 5-month-old dysf -/mice, treated, or not, with halofuginone from 4 weeks to 5 months of age, were stained with H&E. Large degenerated areas with infiltrating immune cells (e.g., macrophages, yellow arrowheads in Fig. 4A ) and numerous centrally nucleated myofibers (i.e., regenerated myofibers, black arrows in Fig. 4A ) were observed in the muscle sections of the non-treated mice (Fig. 4A , Non-treated). In contrast, improved histopathology was demonstrated in the halofuginone-treated mice, with less inflammation and fewer myofibers with central nuclei (Fig. 4A, Halo) . Quantitative analysis of 1000-1200 myofibers per mouse revealed that halofuginone significantly decreases the percentage of centrally nucleated myofibers out of the total number of myofibers (54.5 ± 0.17% and 47 ± 0.18% in non-treated and halofuginone-treated mice, respectively; n = 5; P < 0.0001). Myofiber diameter distribution was also evaluated in these sections. The myofiber diameters were clustered in bin intervals of 0.5 m, and the percentage of myofibers in each group was calculated as the proportion of the total number of myofibers per treatment. Treatment with halofuginone resulted in a noticeable shift of the myofiber distribution curve toward the higher myofiber diameters compared to the non-treated distribution (Fig. 4B ). Mean myofiber diameter was significantly higher in the halofuginone-treated mice than in their non-treated counterparts ( Fig. 4C) . Physiological muscle performance test on the RotaRod with halofuginone-treated or non-treated mice at the age of 5 months revealed that halofuginone markedly increases motor function and coordination: halofuginone-treated mice stayed on the RotaRod about 2.5 times longer than the non-treated mice (Fig. 4D ).
Discussion
Dysferlinopathies are considered a late-onset MD with disease manifestation during the patient's second or even third decade of life [16, 49, 50] . Dysferlinopathies exhibit a milder level of fibrosis than DMD or CMD [51, 52] . However, being a genetically inherited disease [53, 54] , early dystrophic symptoms are probably present from birth. Some dystrophic changes have been reported to appear in the distal muscles of 2-month-old dysf -/- [55] and A/J mice [14] .
Nevertheless, our results, in agreement with others [56, 57] , demonstrate that in dysf -/mice, fibrosis is already present at 4 weeks of age, suggesting the initiation of inflammation and cycles of myofiber degeneration-regeneration leading to fibrosis long before the appearance of the disease phenotype. The fact that fibrosis levels almost doubled from 4 weeks to 5 months of age in dysf -/mice, together with earlier reports on pathological signs in young patients and mice [14, 16, 20] , indicates that the disease is already actively progressing in the early stages of life.
One of the reasons for the early appearance of fibrosis is due to delayed ability of dysf /myoblasts to fuse and form large myotubes compared to their Wt counterparts as was observed in primary cultures derived from 5-week-old mice (Fig. 1) . The delayed fusion of the myoblasts was manifested by the appearance of thinner myotubes compared to the Wt ones. One of the reasons for this phenomenon might be impairment in the myotubes' ability to form actin filaments ( Fig. 2) , which are crucial for cell movement and the cell-cell fusion process [44, 45, [58] [59] [60] . It has also been demonstrated that under local membrane-injury protocols, dysferlin recruitment to the injury site is impaired if the formation of actin filament protrusions is inhibited [61] . Because dysferlin plays a main role in myofiber formation and regeneration [12] , these results reinforce dysferlin's role in muscle-fusion events in dysf -/mice as young as 5 weeks of age. Halofuginone has been reported to improve the myotube fusion index of 5-week-old dysf -/mice [27] . Here, we demonstrated the actual fusing activity under SEM: the halofuginone-treated myofibers actively fused, as observed by the many threads of actin filaments connecting several cells, whereas the non-treated myofibers presented barely any fusion activity (Fig. 2) . Our evidence implies that these filaments are lamellipodia resulting from actin polymerization, causing finger-like actinbased protrusions at the muscle cells' fusion sites [44, 60, 62] . This reorganization of actin cytoskeletal structures, as a result of actin or actin-regulatory protein phosphorylation, is mediated by the PI3K/Akt-signal-transduction pathway [63, 64] . Halofuginone has been reported to enhance Akt phosphorylation levels in association with its promotive effect on satellite cell survival, differentiation and myotube fusion in different MD mouse models [27] [28] [29] [30] . Therefore, it is plausible that halofuginone also increases lamellipodium formation via the PI3K/Aktsignaling pathway.
Cellular vesicles have been shown to assist in the trafficking of cell-adhesion molecules
and/or fusogenic proteins to the plasma membrane [60, 65] . Recently, halofuginone has been shown to rescue lysosomal trafficking to the sarcolemma in myoblasts and myofibers, probably in a synaptotagmin-7-dependent manner [31] . It may well be that the promotive effects of halofuginone on dysf -/muscle cell fusion are also due, at least in part, to its role in the enhancement of lysosome trafficking and exocytosis during myotube-fusion processes.
We previously demonstrated halofuginone's ability to inhibit dystrophic symptoms in dysf -/mice at 12 months of age, when provided for short periods prior to and during the disease outburst and phenotype appearance [27] . Here, halofuginone's ameliorative effects on muscle function and histopathology are demonstrated at the early stages of the dystrophic changes' appearance, during the first months of life. At a very early age, halofuginone affected multiple steps in the disease's progression. First, early treatment of dysf -/mice with halofuginone reduced muscle histopathology in general and muscle fibrosis in particular ( Fig. 3) , probably by inhibiting myofibroblast differentiation to fibroblasts [23] , and reducing the infiltration of inflammatory cells observed in other MDs [26, 29] . Second, halofuginone increased myofiber diameter ( Fig. 4) and decreased the number of centrally nucleated myofibers, in agreement with our previous reports [25, 26] , suggesting an ameliorative effect on the repeated degeneration-regeneration cycles and loss of myofibers. The outcome of all of these beneficial effects is better generation of force and muscle performance [66, 67] . Indeed, we found a marked increase in physiological muscle motor coordination and function (Fig. 4D ).
In accordance with the fibrosis reduction in the dysf -/hindlimb muscle, Smad3 phosphorylation levels were greatly reduced by halofuginone treatment (Fig. 3) . It is accepted that halofuginone's mode of action involves the inhibition of Smad3 phosphorylation downstream of TGFβ signaling [28] . Halofuginone has also been shown to inhibit prolyl-tRNA synthetase activity in Th17 cells under conditions of amino acid starvation [34, 35, 68] , by forming a ternary complex via halofuginone's hydroxyl group with ATP and the enzyme, thus acting as an ATP-competitive inhibitor [69, 70] . A very recent study of ours reported the requirement of halofuginone's hydroxyl group for its promotive effect on fibrosis in mdx mice [71] , raising the possibility that prolyl-tRNA synthetase inhibition by halofuginone plays a part in the latter's effects on fibrosis in MDs, probably at early stages of the disease.
Conclusions
We demonstrate the very early appearance of dystrophic changes in dysf -/mouse muscles; these are manifested by lower fusion index, increased degeneration-regeneration cycles and fibrosis, and attenuated levels of myofiber hypertrophy resulting in lower muscle motoric abilities. The reduced hypertrophy is probably due to delayed myoblast fusion and defects in the myotube's ability to fuse properly, due to the absence of dysferlin. Halofuginone affects this cascade of events, and acts as an efficient reagent for the improvement of muscle cells' abilities to fuse and form mature functioning myofibers, as well as for the amelioration of muscle histopathology and function at very early stages of disease initiation. Current treatments for dysferlinopathy focus on patients post-disease onset [18, 19] . The results presented here offer new opportunities for early pharmaceutical treatment in dysferlinopathies with favorable outcomes at later stages of life; moreover, halofuginone is a likely candidate to fulfill the requirements for such a treatment. Asterisks represent significant differences within treatments at the same age at *P < 0.05 and **P < 0.001. (C) Western blot analysis of the phosphorylation levels of Smad3 (P-Smad3) in protein lysates from hindlimb muscles of 5-month-old dysf -/mice injected with halofuginone (Halo) or saline (Non-treated). Densitometry analysis was normalized to total Smad2/3 and is presented as fold-induction. Results are presented as mean ± SE (n = 3). Asterisk represents significant difference within treatments (P < 0.05).
Figure legends
Fig. 4. Halofuginone improves muscle histopathology and motor coordination of 5-month-old
dysf -/mice. Mice were treated, or not, with halofuginone as described in Fig. 3 
